New Jersey District Court Rules For Ranbaxy In Glaxo Patent Suit

Law360, New York (April 7, 2004, 12:00 AM EDT) -- The U.S. District Court for the District of New Jersey has ruled that Ranbaxy Laboratories’ generic version of GlaxoSmithKline's antibiotic Ceftin does not infringe patents held by Glaxo.

The Indian generic drug maker has been selling its antibiotic, cefuroxime axetil, since 2001, when a federal appeals court vacated a preliminary injunction GlaxoSmithKline had won from a lower court in October 2000, according to Ranbaxy.

Ceftin had global sales of $404 million in 2003, GlaxoSmithKline said.

Ranbaxy reported U.S. cefuroxime axetil sales of $134.8 million in 2003....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.